# Data Sheet (Cat.No.TP2207)

TargetMol

## Pasireotide Acetate

### Chemical Properties



CAS No. : 396091-76-2

Formula: C60H70N10O11

Molecular Weight: 1107.26

Storage: Store at low temperature,Keep away from moisture,
Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

### Biological Description

| | |
|---|---|
| Description | Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively. |
| Targets(IC50) | Somatostatin |
| In vitro | Pasireotide (SOM230) acetate enhances agonist activity at growth inhibitory receptors with pKi of 8.2, 9.0, 9.1, less than 7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively. |
| In vivo | **METHODS**: Pasireotide (SOM230) acetate (160 mg/kg, subcutaneous injection, four months) was administered to a MEN1 transgenic mouse model, and the effects of Pasireotide (SOM230) acetate on insulin secretion, glucose levels, tumor growth and survival were tested.<br>**RESULTS** Pasireotide (SOM230) acetate significantly decreased serum insulin, increased serum glucose, decreased tumor size and increased Pdx1-Cre cell apoptosis. [1] |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 50 mg/mL (45.16 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 0.9031 mL | 4.5157 mL | 9.0313 mL |
| 5 mM | 0.1806 mL | 0.9031 mL | 1.8063 mL |
| 10 mM | 0.0903 mL | 0.4516 mL | 0.9031 mL |
| 50 mM | 0.0181 mL | 0.0903 mL | 0.1806 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Quinn TJ, et al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152(6):1068-77.
Chakrabarti J, Pandey R, Churko J M, et al. Development of Human Pituitary Neuroendocrine Tumor Organoids to Facilitate Effective Targeted Treatments of Cushing's Disease. Cells. 2022, 11(21): 3344.
Zhao Z, Gong F, Duan L, et al. Somatostatin receptor ligands suppressed proliferation and lipogenesis in 3T3-L1 preadipocytes. Basic & Clinical Pharmacology & Toxicology. 2022
Lewis I, et al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003 Jun 5;46(12):2334-44.
Imhof AK,et al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum. 2011 Aug;63(8):2352-62.
Mallick S, Chakrabarti J, Eschbacher J, et al.Genetically Engineered Human Pituitary Corticotroph Tumor Organoids Exhibit Divergent Responses To Glucocorticoid Receptor Modulators.Translational Research.2023